RBC Capital Updates Top 30 Global Stock Picks for 2026

RBC Capital Refreshes Top 30 Global Ideas List

RBC Capital has released its updated Top 30 Global Ideas list for 2026. Led by Graeme Pearson and Mark Odendahl, this quarterly review highlights high-conviction, long-term stock selections based on upside potential.

Portfolio Changes and Performance

Apotex Health, Canadian National Railway, and Lonza were added; three stocks were removed. The list returned 11.1% in Q2/26 (MSCI World: 12.8%). Since late 2019, the Top 30 delivered a 13.9% compound annual return, outperforming the benchmark's 13.4%.

New High-Conviction Additions

Canadian National Railway (CNR)

Favored for discounted valuation, improving network fundamentals, and strong earnings from grain volumes and intermodal gains. Capacity investments are set to drive operating leverage.

Apotex Health (APTX)

A generics company with strong Canadian and U.S. market share. First-to-market strength capitalizes on brand drug loss of exclusivity, ensuring high return on invested capital.

Lonza (LONN)

Positioned as an attractive earnings-per-share compounder. RBC Capital believes market concerns are misframed, offering an entry point for long-term investors.

Summary Outlook

RBC Capital's refined Top 30 list signals strategic long-term growth. Detailed rationales guide informed investment decisions.

FAQ

Q: What is the RBC Capital Top 30 Global Ideas list?

A: A quarterly updated list of 30 high-conviction, long-term global stock selections by RBC Capital.

Q: Which companies were newly added to the list?

A: Apotex Health, Canadian National Railway, and Lonza.

Source: Investing.com